D‐dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial
Alexander T. Cohen(King's College London), Paul Burton(Janssen (United States)), Theodore E. Spiro(Bayer (United States)), Alex C. Spyropoulos(Northwell Health), Victor F. Tapson(Cedars-Sinai Medical Center), Harry R. Büller(Center for Vascular Biology Research), Lloyd Haskell(Johnson & Johnson (United States)), Geno J. Merli(Thomas Jefferson University), Yoriko DeSanctis(Bayer (United States)), Alexandre Mebazaa(Délégation Paris 5), Dayi Hu(Peking University People's Hospital), Martin Homering(Bayer (Germany)), R. Hull(Foothills Medical Centre), Sebastian Schellong(Krankenhaus Dresden-Friedrichstadt)
Cited by 115
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
|European Heart Journal|2014|3.1k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k